Further Information
CDKN2A Antibody: ARF, MLM, P14, P16, P19, CMM2, INK4, MTS1, TP16, CDK4I, CDKN2, INK4A, MTS-1, P19ARF, P16INK4, P16INK4A, P16-INK4A, Cyclin-dependent kinase 4 inhibitor A
WB: 1 - 2 μg/mL; IHC: 5 μg/mL; IF: 20 μg/mL
Antibody validated: Western Blot in human samples; Immunohistochemistry and Immunofluorescence in human samples. All other applications and species not yet tested.
CDKN2A Antibody: The CDKN2A locus gives rise to 2 distinct transcripts from different promoters. The transcripts have been designated p16(INK4A) and p14(ARF). This chromosomal region undergoes a number of inversions, translocations, heterozygous deletions, and homozygous deletions in a variety of malignant cell lines including those from glioma, non-small cell lung cancer, leukemia, and melanoma. Deletion of the region containing CDKN2A is found in more than half of all melanoma cell lines. Conversely, transfection of CDKN2A suppressed the growth of two independent mesothelioma cell lines, suggesting that inactivation of the CDKN2 gene is an essential step in the etiology of malignant mesotheliomas. CDKN2A induces a G1 cell cycle arrest by inhibiting the phosphorylation of the Rb protein by the cyclin-dependent kinases CDK4 and CDK6. CDKN2A is expressed as at least three distinct isoforms.
- Stone et al. Cancer Res. 1995; 55:2988-94.
- Kamb et al. Nature Genet. 1994; 8:22-6.
- Kratzke et al. J. Nat. Cancer Inst. 1995; 87:1870-5.
- Stott et al. EMBO J. 1998; 17:5001-14.
CDKN2A Antibody is supplied in PBS containing 0.02% sodium azide.
1 mg/mL
Unconjugated
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Anti-CDKN2A antibody (8975) was raised against a peptide corresponding to 17 amino acids near the carboxy terminus of human CDKN2A.
The immunogen is located within the last 50 amino acids of CDKN2A.
Human CDKN2A has 6 isoforms, including isoform 1 (156aa, 17kD), isoform 2 (105aa, 11kD), isoform 3 (116aa, 12kD), isoform 5 (167aa, 18kD), isoform tumor suppressor ARF (132aa, 14kD) and isoform smARF (85aa, 9kD). Mouse CDKN2A has 4 isoforms, including isoform 1 (168aa, 18kD), isoform 2 (125aa, 14kD), isoform tumor suppressor ARF (169aa, 19kD) and isoform smARF (125aa, 14kD). Rat CDKN2A has two isoforms, including isoform 1 (159aa, 17kD) and isoform ARF (160aa, 17kD).
8975 can detect only human isoforms 1, 2 and 5, but cannot detect mouse and rat.
1029
cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4)
CDKN2A
Homo sapiens
Liquid
PREDICTED MOLECULAR WEIGHT:
Predicted: 17kD
Observed: 17kD
NP_000068
4502749
CDKN2A Antibody is affinity chromatography purified via peptide column.
Signal Transduction,Homeostasis,Cancer
P42771
Optimal dilutions for each application to be determined by the researcher.
KO Validation (Figure 1): Anti-CDKN2A antibodies (8975) specificity was further verified by CDKN2A specific knockout. CDKN2A signal was not detected in CDKN2A knockout 293 cells as compared to that in control wild type cells.
Independent Antibody Validation in Cell lines (Figure 2) shows similar CDKN2A expression profile in human cell lines detected by two independent anti-CDKN2A antibodies that recognize different epitopes, 4211 against N-terminus domain and 8975 against the C-terminus domain. CDKN2A proteins are detected only in 293, HeLa and HepG2 cell lines by the two independent antibodies.